Evidence map›Paper›PMID 35982065›Full record

ArticleScientific reports2022

Considering epitopes conservity in targeting SARS-CoV-2 mutations in variants: a novel immunoinformatics approach to vaccine design.

Mohammad Aref Bagherzadeh, Mohammad Izadi, Kazem Baesi, Mirza Ali Mofazzal Jahromi, Majid Pirestani

Abstract read
In one paragraph

Article in Scientific reports, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed.

  1. Article
  2. Multi-Epitope mRNA Vaccine TargetingBioinformatics and biology insights · 2026
    Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Review
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Mohammad Aref BagherzadehStudent Research Committee, Jahrom University of Medical Sciences, Jahrom, Iran.ORCID http://orcid.org/0000-0002-7109-4476
Mohammad IzadiStudent Research Committee, Jahrom University of Medical Sciences, Jahrom, Iran.
Kazem BaesiDepartment of Virology, Pasteur Institute of Iran, Tehran, Iran.
Mirza Ali Mofazzal JahromiZoonoses Research Center, Jahrom University of Medical Sciences, Jahrom, Iran. alimofazzal@yahoo.com.
Majid PirestaniParasitology and Entomology Department, Faculty of Medical Sciences, Tarbiat Modares University, Tehran, Iran. pirestani@modares.ac.ir.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) has gained mutations at an alarming rate in the past years. Developing mutations can increase the virus's pathogenicity and virulence; reduce the efficacy of vaccines, antibodies neutralization, and even challenge adaptive immunity. So, it is essential to identify conserved epitopes (with fewer mutations) in different variants with appropriate antigenicity to target the variants by an appropriate vaccine design. Yet as, 3369 SARS-CoV-2 genomes were collected from global initiative on sharing avian flu data. Then, mutations in the immunodominant regions (IDRs), immune epitope database (IEDB) epitopes, and also predicted epitopes were calculated. In the following, epitopes conservity score against the total number of events (mutations) and the number of mutated sites in each epitope was weighted by Shannon entropy and then calculated by the Technique for Order of Preference by Similarity to Ideal Solution (TOPSIS). Based on the TOPSIS conservity score and antigenicity score, the epitopes were plotted. The result demonstrates that almost all epitopes and IDRs with various lengths have gained different numbers of mutations in dissimilar sites. Herein, our two-step calculation for conservity recommends only 8 IDRs, 14 IEDB epitopes, and 10 predicted epitopes among all epitopes. The selected ones have higher conservity and higher immunogenicity. This method is an open-source multi-criteria decision-making platform, which provides a scientific approach to selecting epitopes with appropriate conservity and immunogenicity; against ever-changing viruses.

Indexed as

COVID-19Viral VaccinesAnimalsCOVID-19 VaccinesEpitopes, B-LymphocyteEpitopes, T-LymphocyteHumansMolecular Docking SimulationMutationSARS-CoV-2Spike Glycoprotein, CoronavirusCOVID-19 VaccinesEpitopes, B-LymphocyteEpitopes, T-LymphocyteSpike Glycoprotein, Coronavirusspike protein, SARS-CoV-2Viral Vaccines

Identifiers

PMID35982065
PMCPMC9386201

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.